ACADIA Pharmaceuticals Inc.

ACAD Healthcare Biotechnology

ACADIA Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 11.9% from fiscal 2024. In the quarter to June 2026, revenue grew 16.4%, EPS grew 12.5% and free cash flow grew 50.3%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

19.12 0.59 −2.99%
Market cap
$3.4B
P/E
8.5×
Fwd P/E
55.6×
Dividend yield
—
F-score
6/9
Altman Z
7.90
Beneish M
−0.89
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

13.68 11.51 9.98 11.24
P/S ratio
3.44 4.20 3.47 3.81
P/FCF ratio
56,296.25 0.00 0.00 0.00
P/Operating CF
48.50 (92.28) 111.70 43.08
P/B ratio
3.93 3.66 3.04 3.32
EV/Sales
2.63 3.43 2.69 2.97
EV/EBITDA
11.14 33.08 33.10 35.22
EV/FCF
43,064.04 (39.55) (35.02) (65.04)
Current Ratio
3.02 3.83 3.59 3.39
Net Debt/EBITDA
(22.52) (41.72) 410.14 (23.36)
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
7.31% 8.69% 10.02% 8.89%
Free Cash Flow Yield
0.00% (2.07%) (2.22%) (1.20%)
Free Cash Flow per Share
(0.15) (0.31) 0.17 0.56
Book value per Share
5.43 7.29 7.32 7.61
Free Cash Flow
(24.94) (52.74) 28.77 95.69
EV/EBIT
11.44 35.08 36.39 39.20
Other line items

Show all line items

Columns are period end dates